- Home
- KDK vs NVCR Comparison
KDK vs NVCR Comparison
Compare KDK & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KDK
- NVCR
- Stock Information
- Founded
- KDK 2018
- NVCR 2000
- Country
- KDK United States
- NVCR Switzerland
- Employees
- KDK N/A
- NVCR N/A
- Industry
- KDK EDP Services
- NVCR Medical/Dental Instruments
- Sector
- KDK Technology
- NVCR Health Care
- Exchange
- KDK Nasdaq
- NVCR Nasdaq
- Market Cap
- KDK 1.3B
- NVCR 1.4B
- IPO Year
- KDK N/A
- NVCR 2015
- Fundamental
- Price
- KDK $9.03
- NVCR $12.81
- Analyst Decision
- KDK Strong Buy
- NVCR Buy
- Analyst Count
- KDK 3
- NVCR 7
- Target Price
- KDK $16.17
- NVCR $28.64
- AVG Volume (30 Days)
- KDK 1.2M
- NVCR 1.3M
- Earning Date
- KDK 11-12-2025
- NVCR 10-30-2025
- Dividend Yield
- KDK N/A
- NVCR N/A
- EPS Growth
- KDK N/A
- NVCR N/A
- EPS
- KDK N/A
- NVCR N/A
- Revenue
- KDK $16,079,999.00
- NVCR $642,269,000.00
- Revenue This Year
- KDK N/A
- NVCR $6.68
- Revenue Next Year
- KDK N/A
- NVCR $7.01
- P/E Ratio
- KDK N/A
- NVCR N/A
- Revenue Growth
- KDK N/A
- NVCR 11.17
- 52 Week Low
- KDK $5.77
- NVCR $10.87
- 52 Week High
- KDK $10.48
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- KDK N/A
- NVCR 40.60
- Support Level
- KDK N/A
- NVCR $13.53
- Resistance Level
- KDK N/A
- NVCR $14.22
- Average True Range (ATR)
- KDK 0.00
- NVCR 0.62
- MACD
- KDK 0.00
- NVCR -0.17
- Stochastic Oscillator
- KDK 0.00
- NVCR 15.96
About KDK Kodiak AI Inc. Common Stock
Kodiak AI Inc is engaged in the commercial trucking industry and the public sector, based on AI-powered autonomous vehicle technology.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.